Vital Signs: Colorectal Cancer Screening Among Adults Aged 50-75 Years -- United States, 2008

Richardson, L. C.; Rim, S. H.; Plescia, M.
July 2010
MMWR: Morbidity & Mortality Weekly Report;7/9/2010, Vol. 59 Issue 26, p838
Background: Colorectal cancer (CRC) remains the second leading cause of cancer deaths in the United States and the leading cause of cancer deaths among nonsmokers. Statistical modeling indicates that, if current trends in health behaviors, screening, and treatment continue, U.S. residents can expect to see a 36% decrease in the CRC mortality rate by 2020, compared with 2000. Methods: Every 2 years, CDC uses Behavioral Risk Factor Surveillance System data to estimate up-to-date CRC screening prevalence in the United States. Adults aged ≥50 years were considered to be up-to-date with CRC screening if they reported having a fecal occult blood test (FOBT) within the past year or lower endoscopy (i.e., sigmoidoscopy or colonoscopy) within the preceding 10 years. Prevalence was calculated for adults aged 50-75 years based on current U.S. Preventive Services Task Force recommendations. Results: For 2008, the overall age-adjusted CRC screening prevalence for the United States was 62.9% among adult respondents aged 50-75 years, increased from 51.9% in 2002. Among the lowest screening prevalences were those reported by persons aged 50-59 years (53.9%), Hispanics (49.8%), persons with lower income (47.6%), those with less than a high school education (46.1%), and those without health insurance (35.6%). Conclusions: CRC screening rates continue to increase in the United States. Underscreening persists for certain racial/ethnic groups, lower socioeconomic groups, and the uninsured. Implications for Public Health Practice: Health reform is anticipated to reduce financial barriers to CRC screening, but many factors influence CRC screening. The public health and medical communities should use methods, including client and provider reminders, to ensure test completion and receipt of follow-up care. Public health surveillance should be expanded and communication efforts enhanced to help the public understand the benefits of CRC screening.


Related Articles

  • Surgical treatment for rectal cancer: An international perspective on what the medical gastroenterologist needs to know. Lindsetmo, Rolv-Ole; Yong-Geul Joh; Delaney, Conor P.; Yamamoto, Takayuki // World Journal of Gastroenterology;6/7/2008, Vol. 14 Issue 21, p3281 

    Rectal cancer accounts for one third of all colorectal cancers. The age adjusted death rates from colorectal cancer have declined over recent decades due to a combination of colorectal cancer screening, improved diagnostic tests, improved standardized surgical technique, improved medical...

  • Colonoscopy vs Sigmoidoscopy: New Studies Fuel Ongoing Debate. Schmidt, Charlie // JNCI: Journal of the National Cancer Institute;9/19/2012, Vol. 104 Issue 18, p1350 

    The article discusses studies that fuelled debates over endoscopy in screening colorectal cancer. A study by Robert Schoen et al in the May 21, 2012 issue of the "New England Journal of Medicine" showed that sigmoidoscopy reduced colon cancer incidence by 21% and mortality by 50%. Nancy Baxter...

  • German Bowel Cancer Center: An Attempt to Improve Treatment Quality. Jannasch, Olof; Udelnow, Andrej; Wolff, Stefanie; Lippert, Hans; Mroczkowski, Pawel // Gastroenterology Research & Practice;5/3/2015, Vol. 2015, p1 

    Background. Colorectal cancer remains the second most common cause of death from malignancies, but treatment results show high diversity. Certified bowel cancer centres (BCC) are the basis of a German project for improvement of treatment. The aim of this study was to analyze if certification...

  • Factors affecting mortality in emergency surgery in cases of complicated colorectal cancer. Kızıltan, Remzi; Yılmaz, Özkan; Aras, Abbas; Çelik, Sebahattin; Kotan, Çetin // Medicinski Glasnik;Feb2016, Vol. 13 Issue 1, p62 

    Aim To evaluate retrospectively demographic, clinical and histopathological variables effective on mortality in patients who had undergone emergency surgery due to complicated colorectal cancer. Methods A total of 39 patients underwent urgent surgical interventions due to complicated colorectal...

  • Up-Regulation of MicroRNA-145 Associates with Lymph Node Metastasis in Colorectal Cancer. Yuan, Wei; Sui, Chenguang; Liu, Qian; Tang, Wanyan; An, Huaying; Ma, Jie // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Metastasis is the main cause of mortality in patients with solid tumours. Identifying the exact molecules associated with CRC metastasis may be crucial to understand the process, which might also be translated to the diagnosis and treatment of CRC. In this study, we investigate the association...

  • Colorectal Cancer: Exploring Awareness in Lebanon. Nemer, Hana A.; Hejase, Ale J.; Hejase, Hussin J.; Othman, Mahmoud; Chawraba, Mona; Trad, Mohammad Ali // Journal of Middle East & North Africa Sciences;2016, Vol. 2 Issue 10, p10 

    Background: In 2014, the World Health Organization (WHO) has identified Colorectal Cancer (CRC) as the fourth leading cause of cancer-related deaths (694,000 deaths) after lung (1.59 million deaths), liver (745,000 deaths) and stomach (723,000 deaths) cancers. Thus, CRC awareness is needed in...

  • The Impact of Colorectal Cancer Screening in a Veteran Hospital Population. TROMBOLD, JOHN; FARMER, RUSSELL W.; McCAFFERTY, MICHAEL // American Surgeon;Mar2013, Vol. 79 Issue 3, p296 

    Colon and rectal cancer is the second most common cause of cancer death in the United States. Screening effectively decreases colorectal cancer mortality. This study aims to evaluate the impact of colorectal cancer screening within a Veterans Affairs Medical Center and treatment outcomes....

  • PD-0023 VALIDATION STUDY OF A BLOOD-BASED GENE EXPRESSION SIGNATURE FOR COLORECTAL CANCER DETECTION. Xu, Q.; Ye, X.; Wu, F.; Meng, X. // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii13 

    No abstract available.

  • A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). Avallone, Antonio; Piccirillo, Maria Carmela; Aloj, Luigi; Nasti, Guglielmo; Delrio, Paolo; Izzo, Francesco; Di Gennaro, Elena; Tatangelo, Fabiana; Granata, Vincenza; Cavalcanti, Ernesta; Maiolino, Piera; Bianco, Francesco; Aprea, Pasquale; De Bellis, Mario; Pecori, Biagio; Rosati, Gerardo; Carlomagno, Chiara; Bertolini, Alessandro; Gallo, Ciro; Romano, Carmela // BMC Cancer;2/8/2016, Vol. 16, p1 

    Background: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the second cause of cancer deaths in both sexes. Therefore, research in this field remains of great interest. The approval of bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics